News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Daiichi Sankyo Co Ltd. Upbeat on Drug to Prevent Strokes and Clots
February 21, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
TOKYO, Feb 21 (Reuters) - Japan's Daiichi Sankyo Co Ltd said on Thursday it was highly satisfied with mid-stage results for a key drug to prevent strokes and clots, and would move on to late-stage trials despite fierce competition in the field.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
Asia
Europe
Daiichi Sankyo
MORE ON THIS TOPIC
Depression
Alto Digs Into Exploratory Outcomes as Depression Drug Misses Phase II Endpoint
June 27, 2025
·
2 min read
·
Tristan Manalac
Immunology and inflammation
Nektar Declares Phase IIb Eczema Win for Rezpeg—But Analysts Unconvinced
June 25, 2025
·
3 min read
·
Tristan Manalac
Gene therapy
Sangamo’s ‘Positive’ Phase I/II Data for Fabry Gene Therapy Opens Path to FDA
June 24, 2025
·
3 min read
·
Tristan Manalac
Artificial intelligence
In latest AI Play, Sanofi Bets $630M+ for Formation Bio’s JAK/SYK Blocker
June 24, 2025
·
2 min read
·
Tristan Manalac
